Access

Article


Nature Medicine 10, 696 - 703 (2004)
Published online: 6 June 2004 | doi:10.1038/nm1059

LARGE can functionally bypass alpha-dystroglycan glycosylation defects in distinct congenital muscular dystrophies

Rita Barresi1, Daniel E Michele1, Motoi Kanagawa1, Hollie A Harper1, Sherri A Dovico1, Jakob S Satz1, Steven A Moore2, Wenli Zhang3, Harry Schachter3, Jan P Dumanski4, Ronald D Cohn1, Ichizo Nishino5 & Kevin P Campbell1


Several congenital muscular dystrophies caused by defects in known or putative glycosyltransferases are commonly associated with hypoglycosylation of alpha-dystroglycan (alpha-DG) and a marked reduction of its receptor function. We have investigated changes in the processing and function of alpha-DG resulting from genetic manipulation of LARGE, the putative glycosyltransferase mutated both in Largemyd mice and in humans with congenital muscular dystrophy 1D (MDC1D). Here we show that overexpression of LARGE ameliorates the dystrophic phenotype of Largemyd mice and induces the synthesis of glycan-enriched alpha-DG with high affinity for extracellular ligands. Notably, LARGE circumvents the alpha-DG glycosylation defect in cells from individuals with genetically distinct types of congenital muscular dystrophy. Gene transfer of LARGE into the cells of individuals with congenital muscular dystrophies restores alpha-DG receptor function, whereby glycan-enriched alpha-DG coordinates the organization of laminin on the cell surface. Our findings indicate that modulation of LARGE expression or activity is a viable therapeutic strategy for glycosyltransferase-deficient congenital muscular dystrophies.


MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

Neurobiology Full circle to cobbled brain

Nature News and Views (25 Jul 2002)

Glycosylation eases muscular dystrophy

Nature Medicine News and Views (01 Jul 2004)

See all 4 matches for News And Views